Watson, KL, Yi, R, and Moorehead, RA. Transgenic overexpression of the miR-200b/200a/429 cluster inhibits mammary tumor initiation. Translational Oncology 2021: 14(12): 101228. doi: 10.1016/j.tranon.2021.101228
Roth, MJ and Moorehead, RA. The miR-200 family in normal mammary gland development. BMC Developmental Biology 2021: 21(1): 21. doi: https://doi.org/10.1186/s12861-021-00243-7
Simpson, K., Conquer-Van Heumen, G., Watson, KL., Roth, M., Martin, CJ, Moorehead, RA. Re-expression of miR-200s in claudinâlow mammary tumor cells alters cell shape and reduces proliferation and invasion potentially through modulating other miRNAs and SUZ12 regulated genes. Cancer Cell International. 2021: 21(1):89. doi: https://doi.org/10.1186/s12935-021-01784-4
Nidogen 1 regulates proliferation and migration/invasion in murine claudin-low mammary tumor cells. Jagroop, R, Martin, CJ, Moorehead, RA. Oncology Letters. 2021: 21(1):52. doi: 10.3892/ol.2020.12313.
Isolated soy protein promotes mammary tumor development induced by the type I insulin-like growth factor receptor in transgenic mice. Watson KL, Sauerzopf K, Moorehead, RA. Nutrition and Cancer. 2021: 73(8): 1340-1349 doi: https://doi.org/10.1080/01635581.2020.1795210
Polycomb repressor complex 2 function in breast cancer (Review). Martin, CJ., Moorehead, RA. International Journal of Oncology. 2020: 57(5) 1085-1094. doi.org/10.3892/ijo.2020.5122.
Rodent Models Assessing Mammary Tumor Prevention by Soy or Soy Isoflavones. Moorehead, RA. Genes (Basel). 2019 Jul 26;10(8). pii: E566. doi: 10.3390/genes10080566. Review.
Integrative analysis of copy number and gene expression data identifies potential oncogenic drivers that promote mammary tumor recurrence. Jones, RA and Moorehead RA. Genes Chromosomes Cancer. 2019 Jun;58(6):381-391. doi: 10.1002/gcc.22729.
Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGFIR-driven lung cancer. Jones RA, Franks SE, Moorehead RA. PLoS One. 2018 Nov 9;13(11):e0206948. doi: 10.1371/journal.pone.0206948.
The miR-200b/200a/429 cluster prevents metastasis and induces dormancy in a murine claudin-low mammary tumor cell line. Watson KL, Jones RA, Bruce A, Moorehead RA. Exp Cell Res. 2018 Aug 1;369(1):17-26. doi: 10.1016/j.yexcr.2018.04.024.
A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206. Chorner PM, Moorehead RA. PLoS One. 2018 Feb 22;13(2):e0193344. doi: 10.1371/journal.pone.0193344.
Re-expression of miR-200c suppresses proliferation, colony formation and in vivo tumor growth of murine claudin-low mammary tumor cells. Jones R, Watson K, Bruce A, Nersesian S, Kitz J, Moorehead R. Oncotarget. 2017 Apr 4;8(14):23727-23749. doi: 10.18632/oncotarget.15829.
Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells. Saleh S, Thompson DE, McConkey J, Murray P, Moorehead RA. BMC Cancer. 2016 Jun 10;16:359. doi: 10.1186/s12885-016-2396-9.
BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. Franks SE, Jones RA, Briah R, Murray P, Moorehead RA. BMC Res Notes. 2016 Mar 1;9:134. doi: 10.1186/s13104-016-1919-4. P
Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis. Franks SE, Briah R, Jones RA, Moorehead RA. Oncotarget. 2016 Jan 19;7(3):3297-316. doi: 10.18632/oncotarget.6489.
High levels of dietary soy decrease mammary tumor latency and increase incidence in MTB-IGFIR transgenic mice. Watson KL, Stalker L, Jones RA, Moorehead RA. BMC Cancer. 2015 Feb 6;15:37. doi: 10.1186/s12885-015-1037-z.
IGF-IR mediated mammary tumorigenesis is enhanced during pubertal development. Jones RA, Watson KL, Campbell CI, Moorehead RA. PLoS One. 2014 Sep 26;9(9):e108781. doi: 10.1371/journal.pone.0108781.
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors. Stalker L, Pemberton J, Moorehead RA. Cancer Cell Int. 2014 Sep 5;14(1):89. doi: 10.1186/s12935-014-0089-5.
Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice. Watson KL, Moorehead RA. BMC Cancer. 2013 Aug 7;13:375. doi: 10.1186/1471-2407-13-375.
Caveolin-1 expression is elevated in claudin-low mammary tumor cells. Thompson DE, Siwicky MD, Moorehead RA. Cancer Cell Int. 2012 Feb 22;12:6. doi: 10.1186/1475-2867-12-6.
Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors. Campbell CI, Moorehead RA. BMC Cancer. 2011 Nov 9;11:480. doi: 10.1186/1471-2407-11-480.
Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature. Franks SE, Campbell CI, Barnett EF, Siwicky MD, Livingstone J, Cory S, Moorehead RA. Oncogene. 2012 Jul 5;31(27):3298-309. doi: 10.1038/onc.2011.486.
Murine mammary tumor cells with a claudin-low genotype. Campbell CI, Thompson DE, Siwicky MD, Moorehead RA. Cancer Cell Int. 2011 Aug 16;11:28. doi: 10.1186/1475-2867-11-28.
ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis. Campbell CI, Petrik JJ, Moorehead RA. Mol Cancer. 2010 Sep 8;9:235. doi: 10.1186/1476-4598-9-235.
Preneoplastic changes persist after IGF-IR downregulation and tumor regression. Jones RA, Petrik JJ, Moorehead RA. Oncogene. 2010 Aug 26;29(34):4779-86. doi: 10.1038/onc.2010.231.
The function of IGF-IR in NNK-mediated lung tumorigenesis. Siwicky MD, Petrik JJ, Moorehead RA. Lung Cancer. 2011 Jan;71(1):11-8. doi: 10.1016/j.lungcan.2010.03.012.
Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Linnerth NM, Siwicky MD, Campbell CI, Watson KL, Petrik JJ, Whitsett JA, Moorehead RA. Neoplasia. 2009 Jul;11(7):672-82.
Reversibility and recurrence of IGF-IR-induced mammary tumors. Jones RA, Campbell CI, Wood GA, Petrik JJ, Moorehead RA. Oncogene. 2009 May 28;28(21):2152-62. doi: 10.1038/onc.2009.79.
The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis. Jones RA, Moorehead RA. J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):407-13. doi: 10.1007/s10911-008-9097-1.
cAMP response element-binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. Linnerth NM, Greenaway JB, Petrik JJ, Moorehead RA. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1248-57. doi: 10.1111/j.1525-1438.2007.01177.
Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor. Jones RA, Campbell CI, Petrik JJ, Moorehead RA. Mol Cancer Res. 2008 May;6(5):819-28. doi: 10.1158/1541-7786.MCR-07-2157.
Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, Moorehead RA. Oncogene. 2007 Mar 8;26(11):1636-44.
IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells. Linnerth NM, Baldwin M, Campbell C, Brown M, McGowan H, Moorehead RA. Oncogene. 2005 Nov 10;24(49):7310-9.
Use of a transgenic mouse model to identify markers of human lung tumors. Linnerth NM, Sirbovan K, Moorehead RA. Int J Cancer. 2005 May 10;114(6):977-82.